Kyverna Therapeutics, Inc.
NASDAQ:KYTX · NASDAQ Global Select
-$0.12 today
Vol 1.11M · Avg 0.94M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $32.2M |
| Short-term Investments | $204.3M |
| Other Current | $5.3M |
| Total Current Assets | $241.7M |
| PP&E (Net) | $9.7M |
| Other Non-current | $5.6M |
| Total Non-current Assets | $15.3M |
| Total Assets | $257.0M |
Analysis
Selected assets total $257.0M for Latest. The largest visible component is Short-term Investments at $204.3M, about 79.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $124.1M +28.4% | $96.6M +178.9% | $34.6M -8.2% | $37.7M -50.4% | $76.1M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $155.2M -18.1% | $189.4M +727.0% | $22.9M +68.5% | $13.6M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $3.7M -19.9% | $4.6M +48.1% | $3.1M +61.8% | $1.9M +89.1% | $1.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $283.0M -2.6% | $290.6M +379.0% | $60.7M +13.9% | $53.3M -30.9% | $77.1M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $5.4M -49.1% | $10.7M +0.4% | $10.6M -14.7% | $12.4M +59.3% | $7.8M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $5.5M +3.6% | $5.3M +34.2% | $3.9M +218.3% | $1.2M +107.8% | $593.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $10.9M -31.7% | $15.9M +9.6% | $14.5M +6.3% | $13.7M +62.8% | $8.4M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $293.8M -3.6% | $304.6M +305.1% | $75.2M +12.4% | $66.9M -21.7% | $85.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.3M +14.7% | $4.6M +6.1% | $4.4M +200.3% | $1.5M +87.7% | $773.0K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 -100.0% | $6.0M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $10.0M +104.6% | $4.9M -50.0% | $9.8M +1629.0% | $565.0K -67.1% | $1.7M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $36.5M +8.1% | $33.8M +70.0% | $19.9M +66.1% | $12.0M -24.9% | $15.9M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $24.7M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 -100.0% | $1.0M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 -100.0% | $6.0K -100.0% | $110.0M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $25.1M +482.6% | $4.3M -30.2% | $6.2M -25.7% | $8.3M -92.8% | $115.8M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $61.5M +61.7% | $38.1M +46.3% | $26.0M +28.5% | $20.2M -84.6% | $131.7M | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.0K | $0 | $0 | $0 | $0 | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$424.8M -61.2% | -$263.5M -93.7% | -$136.0M -79.8% | -$75.7M -61.8% | -$46.8M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $97.0K -7.6% | $105.0K +2525.0% | $4.0K +115.4% | -$26.0K | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 +100.0% | -$0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $232.3M -12.9% | $266.6M +442.1% | $49.2M +5.4% | $46.7M +200.9% | -$46.3M | $9.1B | $7.7B | $3.3B |
| Total Debt | $29.0M +252.2% | $8.2M -9.2% | $9.1M -14.1% | $10.6M +90.2% | $5.6M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$95.1M -7.6% | -$88.4M -245.7% | -$25.6M +5.9% | -$27.2M +61.5% | -$70.5M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$484.08M
Cabaletta Bio, Inc.
NASDAQ:CABA
$468.78M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$438.73M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$386.33M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$343.72M
Silence Therapeutics plc
NASDAQ:SLN
$324.02M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$294.28M
Editas Medicine, Inc.
NASDAQ:EDIT
$253.51M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.71M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does KYTX have?
Kyverna Therapeutics, Inc. (KYTX) reported $124.09M in cash and equivalents in fiscal 2025.
How much debt does KYTX carry?
Kyverna Therapeutics, Inc. (KYTX) reported $29.03M of total debt, with net debt of -$95,061,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.